For patients with atrial fibrillation, a successful catheter ablation can feel like a new lease on life. But for a significant minority, the irregular heart rhythm returns, often within the first year. The standard response is more medication, another procedure, or a resigned acceptance of the condition. StimCardio Medical is betting that the answer, instead, could be a wearable device that gently stimulates the nervous system, aiming to keep the heart in rhythm from the comfort of home.
The Los Angeles-based clinical-stage company recently closed a $30 million Series A financing to advance its lead investigational product, a wrist-worn therapeutic called Rhyvive [BioSpace/PR Newswire, October 2026]. The device is designed as an adjunct to catheter ablation, delivering personalized, non-invasive median nerve stimulation through a closed-loop system that integrates physiological sensing with neuromodulation [BioSpace/PR Newswire, October 2026]. The round, led by John Slump's family office Metis Medtech, will fund a planned pivotal study and preparation for a De Novo submission to the FDA [BioSpace/PR Newswire, October 2026].
The Clinical Wedge
StimCardio's approach is notable for its specific clinical positioning. It is not attempting to replace the gold-standard ablation procedure, but to extend its therapeutic benefit. The company is targeting the autonomic nervous system, which influences heart rate and rhythm, through peripheral nerve stimulation. By applying gentle electrical pulses to the median nerve in the wrist, the Rhyvive device aims to modulate this system to prevent the recurrence of atrial arrhythmias [Neurofounders]. This positions the therapy squarely within the post-procedural care pathway, a period of high clinical need where new, non-invasive options are scarce.
The company's scientific foundation rests on peer-reviewed pilot data. Results from the NeuroPulse study, investigating non-invasive median nerve stimulation to reduce atrial arrhythmia recurrence after AF ablation, were presented as late-breaking clinical science at HRX Live 2026 and simultaneously published in the journal Heart Rhythm [Yahoo Finance, retrieved 2026]. Company-linked materials cite the pilot as showing 90% freedom from atrial arrhythmias at six months among participants using the wearable neuromodulation following their ablation [Hooman Soltanian - LinkedIn, retrieved 2026]. While a pilot study is far from definitive, publication in a major cardiology journal provides a credible foundation for the larger, more rigorous trial the new funding will enable.
The Team and Trajectory
StimCardio, which was formerly known as CardiaCare, has been developing its approach since its founding in 2016 [Crunchbase]. The leadership combines deep clinical and entrepreneurial experience in the cardiovascular space.
| Role | Name | Background |
|---|---|---|
| Chief Scientific Officer & Co-Founder | Amos Ziv | Over 20 years in integrative cardiovascular support as an entrepreneur and clinical research scientist [StimCardio, company overview]. |
| CEO & Co-Founder | Amir Soltanianzadeh | Also founder of Solardis Health Ventures; led the company through its rebranding and recent financing [StimCardio, LSI Alumni Innovator Spotlight, April 2025]. |
| Board Member | John Slump | Founder and CEO of lead investor Metis Medtech [StimCardio, company overview]. |
The $30 million financing round attracted a mix of venture and strategic capital. Alongside lead investor Metis Medtech, participants included Catalyst Health Ventures, corporate strategic investors, and other new and existing backers [BioSpace/PR Newswire, October 2026]. The company has also been part of the HeartX Cardiovascular Accelerator, further embedding it in the medtech ecosystem [StimCardio].
The Regulatory Road Ahead
The capital is earmarked for a clear and costly milestone: the NeuroPulse 2 pivotal study. This trial will be critical for generating the clinical evidence required for a De Novo classification request with the U.S. Food and Drug Administration. The company is actively hiring for roles like a Senior Clinical Research Associate to support this work [StimCardio careers]. The De Novo pathway is appropriate for a novel device with no legally marketed predicate, a classification that, if successful, would create a new regulatory category for this type of therapy.
The path is long and capital-intensive, but the company has structured its initial clinical work to de-risk the proposition. Prior to the NeuroPulse pilot, StimCardio conducted a First-in-Human study, the results of which were presented at the AF Symposium in 2022 and were reported to demonstrate exceptional device safety and usability [Tsahi Holand - LinkedIn, retrieved 2026]. This phased approach from early safety to pilot efficacy now leads to the pivotal phase, which will be the ultimate test of the therapy's value.
An Honest Counterfactual
The ambition is significant, and so are the hurdles. StimCardio is operating in one of the most challenging and expensive sectors: regulated medical devices for a chronic cardiovascular condition. The risks are not merely technical but procedural and commercial.
- Clinical proof. The promising pilot data must be reproduced and validated in a larger, controlled pivotal study. The difference between a 90-patient pilot and a several-hundred-patient pivotal trial is where many investigational devices stumble.
- Commercial adoption. Even with FDA clearance, convincing cardiologists and healthcare systems to adopt a new, post-ablation wearable therapy requires demonstrating not just efficacy, but a clear improvement in patient outcomes and cost-effectiveness over the current standard of watchful waiting or medication.
- Competitive landscape. While direct competitors appear limited,one named competitor is Rivia,the company is effectively creating a new sub-category. This means it must educate the market while also executing flawlessly on development.
The company's most plausible answer to these challenges is its focused clinical strategy. By targeting the very specific and high-need population of post-ablation patients, it aims to prove value in a discrete use case before potentially expanding. The involvement of strategic corporate investors also suggests potential future partnership avenues for commercialization.
The Patient Population in Focus
The disease state is atrial fibrillation, the most common sustained cardiac arrhythmia worldwide. For the patients StimCardio is initially targeting, the journey typically involves symptomatic episodes, a decision to undergo catheter ablation,a procedure that scars heart tissue to block erratic electrical signals,and then the anxious wait to see if the problem returns. Recurrence rates vary but can be as high as 30-40% within the first year, leaving a substantial group in need of better options.
The current standard of care for recurrent AF after an ablation is often a stepped approach. It may begin with anti-arrhythmic drugs, which can have side effects and limited efficacy. For some, a repeat ablation procedure is recommended. For others, especially those who are older or have more complex heart disease, the focus shifts to rate control and stroke prevention rather than rhythm control. A non-invasive, wearable device that could safely reduce the likelihood of recurrence would represent a meaningful shift, moving chronic disease management from the clinic into daily life. The next twelve months for StimCardio will be defined by patient enrollment and data collection, as the pivotal study transforms its pilot promise into pivotal evidence.
Sources
- [BioSpace/PR Newswire, October 2026] StimCardio Closes Oversubscribed $30 Million Series A Financing | https://www.biospace.com/press-releases/stimcardio-closes-oversubscribed-30-million-series-a-financing-to-advance-wearable-therapeutic-for-atrial-fibrillation
- [StimCardio, company overview] About StimCardio | Innovation in Cardiac Care | https://www.stimcardio.com/about-us
- [Neurofounders] StimCardio - Developing a wrist-worn, closed-loop median nerve stimulation device | https://www.neurofounders.co/startups/stimcardio
- [Yahoo Finance, retrieved 2026] NeuroPulse pilot study presentation and publication | https://finance.yahoo.com
- [Hooman Soltanian - LinkedIn, retrieved 2026] NeuroPulse pilot study results | https://www.linkedin.com/in/hooman-soltanianzadeh
- [Crunchbase] StimCardio Medical (formerly CardiaCare) - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/stimcardio-medical
- [StimCardio, LSI Alumni Innovator Spotlight, April 2025] LSI Alumni Innovator Spotlight, CardiaCare CEO Amir Soltanianzadeh | https://www.stimcardio.com/news-articles/lsi-alumni-innovator-spotlight-cardiacare-ceo-amir-soltanianzadeh
- [StimCardio careers] Senior Clinical Research Associate (Senior CRA) | https://www.stimcardio.com/careers/senior-clinical-research-associate-senior-cra
- [Tsahi Holand - LinkedIn, retrieved 2026] First In Human Atrial Fibrillation study results | https://www.linkedin.com/in/tsahi-holand-72044524/
- [StimCardio] HeartX Cardiovascular Accelerator participation | https://www.stimcardio.com